Solara's Q2 FY27 Revenue Up 33% to ₹417.8 Cr, EBITDA More Than Doubles to ₹76.9 Cr
Solara reported its best quarter in five years with Q2 FY27 revenue at ₹417.8 Cr, up 33% YoY. EBITDA more than doubled to ₹76.9 Cr, up 118% YoY. PAT turned positive at ₹28.5 Cr vs loss of ₹10.1 Cr YoY. Net debt reduced by ₹114.1 Cr to ₹500 Cr.
The strong financial performance, including record EBITDA and significant debt reduction, is a material development for the company and its investors, indicating a positive turnaround and improved financial health.
The company reported its best quarter in five years with significant year-on-year growth in revenue, EBITDA, and a turnaround in PAT. The reduction in net debt and improvement in the net debt to EBITDA ratio also contribute to positive sentiment.
Solara Active Pharma Sciences Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company reported its best quarter in five years, with overall revenue growing by 33% year-on-year to ₹4,178 million (₹417.8 crore) and EBITDA more than doubling to ₹769 million (₹76.9 crore), an increase of 118% year-on-year.
The base business, excluding Ibuprofen, was a key growth driver, with revenue up 37% year-on-year to ₹3,273 million (₹327.3 crore) and EBITDA up 68% year-on-year to ₹771 million (₹77.1 crore). The EBITDA margin for the base business expanded by approximately 440 basis points year-on-year to 23.6%. The Ibuprofen business also showed improvement, with revenue up 21% year-on-year to ₹905 million (₹90.5 crore) and the EBITDA loss narrowing significantly to ₹2 million (₹0.2 crore) from ₹87 million (₹8.7 crore) in the previous quarter.
Profit After Tax (PAT) for the quarter was ₹285 million (₹28.5 crore), a significant turnaround from a loss of ₹101 million (₹10.1 crore) in the corresponding quarter of the previous year. Earnings Per Share (EPS) stood at ₹5.92 per share, compared to a loss of ₹2.36 per share in Q2 FY26. The company also reported a reduction in net debt by ₹1,141 million (₹114.1 crore) in the first half of FY27, bringing the net debt to ₹5,000 million (₹500 crore). Consequently, the net debt to EBITDA ratio improved to approximately 1.8x from 3.2x at the end of FY26.
The strategic review of the Ibuprofen business is in its advanced stages, with further updates expected within the next 12 weeks. The company hosted an earnings conference call on Friday, October 16, 2026, at 16:00 IST.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.